Extended Data Fig. 1: Longitudinal changes on secondary efficacy assessments from baseline to week 78. | Nature Aging

Extended Data Fig. 1: Longitudinal changes on secondary efficacy assessments from baseline to week 78.

From: TANGO: a placebo-controlled randomized phase 2 study of efficacy and safety of the anti-tau monoclonal antibody gosuranemab in early Alzheimer’s disease

Extended Data Fig. 1: Longitudinal changes on secondary efficacy assessments from baseline to week 78.

Adjusted mean change from baseline (±SE) up to week 78 on the (a) ADAS-Cog13, (b) MMSE, and (c) ADCS-ADL scores. In panel A, a greater positive change indicates worsening of symptoms; in panels B and C, a greater negative change indicates worsening. Sample sizes for each group at each time point are listed for each panel. Asterisk denotes a significant difference between the high-dose placebo groups (P = 0.0378). Analyses were two-sided at 5% significance level. No adjustments were made for multiple comparisons.

Source data

Back to article page